Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2024-11-12 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
关于开展融资租赁业务暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's financing leasing business and related party transactions. It details the transaction overview, decision and approval procedures by the board and independent directors, related party information, pricing policy, transaction terms, and the impact on the company. It is not a financial report, earnings release, or management discussion but a specific update on financing activities and related party guarantees. The document length is about 2460 characters, which is relatively short and focused on a specific financing transaction. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2024-11-12 Chinese
第四届董事会第三十九次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of resolutions passed at the 39th meeting of the 4th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about board member nominations, board role confirmations, amendments to the company charter, and plans for a shareholders meeting. The content focuses on board and management changes and governance matters, with no financial statements or earnings data. The document is not a full annual or interim report, nor is it a simple announcement of a report. It clearly fits the category of Board/Management Information (MANG) as it announces changes and nominations related to the company's board of directors.
2024-11-07 Chinese
中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司股权激励计划限制性股票第二期解除限售条件成就的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed legal and regulatory opinion from a sponsoring securities firm (中信证券股份有限公司) regarding the achievement of conditions for the second phase of lifting restrictions on restricted stock under an equity incentive plan of 北京康乐卫士生物技术股份有限公司. It includes detailed information about the stock grant dates, lock-up periods, conditions for lifting restrictions, and the approval process by the board and supervisory committee. The document references regulatory rules and compliance with stock incentive management measures and stock exchange listing rules. It is not a general financial report, earnings release, or management discussion, but a formal verification and legal opinion on the lifting of stock restrictions under an equity incentive plan. This fits the category of a Regulatory Filing (RNS) because it is a compliance and regulatory disclosure document that does not fit into other specific categories such as capital updates or management changes. The document length is sufficient and contains substantive content, but it is not a financial report or earnings announcement. Therefore, the best classification is Regulatory Filings (RNS).
2024-11-07 Chinese
关于拟修订《公司章程》公告
Governance Information Classification · 95% confidence The document is an announcement regarding proposed amendments to the company's Articles of Association (公司章程). It details specific changes to governance structure, referencing relevant laws and listing rules. It is not a full report but a regulatory announcement about governance changes requiring shareholder approval. The document is short (697 characters) and does not contain financial data or detailed management discussion. It fits best under Governance Information (CGR) as it relates to internal rules and governance practices.
2024-11-07 Chinese
关于召开2024年第三次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a detailed notice for the 2024 third extraordinary general meeting of shareholders of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items such as amendments to the company charter, board of directors re-election, and supervisory board re-election. It also contains instructions for shareholder registration and proxy voting. The content focuses on the organization and conduct of a shareholders meeting rather than financial results or reports. There is no financial data or earnings information, nor is it a transcript or presentation. The document is not a report publication announcement but a formal meeting notice with agenda and voting details. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or other shareholder meetings.
2024-11-07 Chinese
独立董事提名人声明与承诺（李晓静）
Board/Management Information Classification · 100% confidence The document is a nomination statement and commitment declaration for an independent director candidate (李晓静) for the company's board. It details the qualifications, independence criteria, and legal compliance of the nominee. There is no financial data, no report or results announcement, no meeting materials, no voting results, no legal proceedings, no capital changes, and no earnings or management discussion. The document is a formal announcement related to board/management information, specifically about a board candidate nomination and related compliance statements. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and it is not a report publication or certification, so it does not fall under RPA or RNS.
2024-11-07 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.